Title: Co-Founder and Chief Executive Officer
Company: Pandorum Technologies Pvt. Ltd.
Location: New York City, United States
Tuhin Bhowmick, PhD, Co-Founder and Chief Executive Officer at Pandorum Technologies Pvt. Ltd., has been recognized by Marquis Who’s Who Top Scientists for dedication, achievements, and leadership in biotechnology.
Dr. Bhowmick, an esteemed entrepreneur in the biotechnology sector, co-founded Pandorum Technologies Pvt. Ltd. in his home country in Bengaluru, India, in 2011. Initially serving as the director from 2011 to 2016, he pivoted into the chief executive officer role, where he has been instrumental in the start-up’s success. Specializing in tissue engineering and regenerative medicine, Dr. Bhowmick relies on a proprietary technology platform to develop functional human tissues for therapeutic application and medical research.
Launching Pandorum Technologies Pvt. Ltd. during his doctoral studies, Dr. Bhowmick used a grant from the department of biotechnology to fund his business. Over the past decade, he and his team have developed a technology utilizing Food and Drug Administration-approved, high-quality, clinical-grade human mesenchymal stem cells to promote efficient tissue regeneration in areas like the cornea, liver and lung. Dr. Bhowmick presently has four clinical trial centers in Chicago, Riyadh, Saudi Arabia, New Delhi, India, and Kyoto, Japan. He plans to begin conduct human studies to reverse corneal blindness in 2025.
Beginning his career at the Indian Institute of Science in Bengaluru, where he received his formal education, Dr. Bhowmick was a research associate on campus from 2012 to 2013, then a research scientist between 2013 and 2015. Additionally, he had the opportunity to serve as an EIPOD fellow at the European Molecular Biology Laboratory in Germany from 2015 to 2018.
Dr. Bhowmick possesses a rich educational background that includes a Master of Science in biotechnology from The Maharaja Sayajirao University of Baroda in 2005 and a Doctor of Philosophy in macromolecular crystallography and structural and computational biology from the Indian Institute of Science in 2012. Additionally, he completed postdoctoral work in structural biology at the European Molecular Biology Laboratories in Germany in 2018. Dr. Bhowmick’s extensive educational pursuits have been pivotal to his success in biotechnology.
Active in his professional community, Dr. Bhowmick is affiliated with the Association for Research in Vision and Ophthalmology (ARVO). He is also involved with the Endless Frontier Labs in the Leonard N. Stern School of Business at New York University. Furthermore, Dr. Bhowmick draws satisfaction from giving back by assisting scientists in various capacities in the U.S. and India.
A well-written writer, Dr. Bhowmick has contributed articles to several scholarly journals, including the Journal of Physical Chemistry. Among other accomplishments, he has been invited to participate in reviews and interviews. He also obtained a U.S. patent and recently received an orphan drug designation from the U.S. Food and Drug Administration (FDA). Moreover, Dr. Bhowmick completed the pre-IND meeting with the FDA, validating his preclinical data with animal models.
In light of his success, Dr. Bhowmick has been recognized with a Best Innovator Award for Pandorum Technologies Pvt. Ltd from Times Group of India in 2019. Subsequently, he received a Hot Topic of the Year Award from ARVO in 2023 for the liquid cornea treatment Kuragenx that he and his team developed for treating blind patients.
Born into a family of clinicians, including his grandfather, father and three uncles, Dr. Bhowmick pursued a similar path at the intersection of physics and medicine. Eager to impact the field through biotechnology innovation by helping develop new drugs, he remains passionate about his work. Demonstrating a keen interest in science and technology while coming of age, he is grateful for his family’s continued support in his professional endeavors.
For more information, please visit:
Pandorum Technologies Pvt. Ltd.
Contact Dr. Bhowmick:
